These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37923822)

  • 41. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
    Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
    Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8
    Sierra JM; Secchiari F; Nuñez SY; Iraolagoitia XLR; Ziblat A; Friedrich AD; Regge MV; Santilli MC; Torres NI; Gantov M; Trotta A; Ameri C; Vitagliano G; Pita HR; Rico L; Rovegno A; Richards N; Domaica CI; Zwirner NW; Fuertes MB
    Front Immunol; 2021; 12():745939. PubMed ID: 34616407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities.
    Lv L; Wang H; Shi W; Wang Y; Zhu W; Liu Z; Chen X; Zheng C; Kong W; Li W; Zhu J; Lu H
    Appl Microbiol Biotechnol; 2022 Nov; 106(21):7039-7050. PubMed ID: 36184689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy.
    Xiao R; Mansour AG; Huang W; Chrislip LA; Wilkins RK; Queen NJ; Youssef Y; Mao HC; Caligiuri MA; Cao L
    Mol Ther; 2019 May; 27(5):922-932. PubMed ID: 30833178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
    Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
    Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
    Taube JM; Young GD; McMiller TL; Chen S; Salas JT; Pritchard TS; Xu H; Meeker AK; Fan J; Cheadle C; Berger AE; Pardoll DM; Topalian SL
    Clin Cancer Res; 2015 Sep; 21(17):3969-76. PubMed ID: 25944800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nocardia Rubra Cell Wall Skeleton Up-Regulates T Cell Subsets and Inhibits PD-1/PD-L1 Pathway to Promote Local Immune Status of Patients With High-Risk Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia.
    Chen W; Zhang Y; Zhao C; Shao S; Zhang Y; Li X; Bai X; Guo Q; Liu Q; Tang J; Zhang L
    Front Immunol; 2020; 11():612547. PubMed ID: 33552075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
    Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
    Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4
    Gallotta M; Assi H; Degagné É; Kannan SK; Coffman RL; Guiducci C
    Cancer Res; 2018 Sep; 78(17):4943-4956. PubMed ID: 29945961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
    Durgan K; Ali M; Warner P; Latchman YE
    Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
    Zhang J; Guo Y; Fang H; Guo X; Zhao L
    Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15.
    McArdel SL; Dugast AS; Hoover ME; Bollampalli A; Hong E; Castano Z; Leonard SC; Pawar S; Mellen J; Muriuki K; McLaughlin DC; Bayhi N; Carpenter CL; Turka LA; Wickham TJ; Elloul S
    Cancer Immunol Immunother; 2021 Sep; 70(9):2701-2719. PubMed ID: 34244816
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
    J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
    Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
    Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.